Movement Alert｜Summit Therapeutics PLC Falls 5.46% in Regular Trading, Advances Late-Stage Ivonescimab Bile Duct Cancer Collaboration

Market Focus10-26

On October 26, Summit Therapeutics PLC fell 5.46% in Regular Trading, trading at $14.595 per share, with turnover of $18.6503 million.

The latest disclosed catalyst was the company’s collaboration with ECOG-ACRIN Cancer Research Group to run a Phase 2/3 trial of ivonescimab in first-line advanced biliary tract cancer.

Under the study design, ivonescimab plus gemcitabine and cisplatin will be compared with pembrolizumab or durvalumab combined with the same chemotherapy regimen, with overall survival as the primary endpoint. Trial sites are expected to begin opening in the fourth quarter. The update follows prior Phase 3 data from China in biliary tract cancer, where ivonescimab met overall survival, progression-free survival, and objective response rate endpoints.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment